Ignite Creation Date:
2025-12-24 @ 6:34 PM
Ignite Modification Date:
2026-01-28 @ 4:18 AM
Study NCT ID:
NCT04239157
Status:
RECRUITING
Last Update Posted:
2025-11-18
First Post:
2019-12-31
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Myelomonocytic Leukemia | View |
| None | Myelodysplastic Syndrome | View |
| None | Recurrent Chronic Myelomonocytic Leukemia | View |
| None | Recurrent Myelodysplastic Syndrome | View |
| None | Refractory Chronic Myelomonocytic Leukemia | View |
| None | Refractory Myelodysplastic Syndrome | View |
Keywords: